Search This Blog

Thursday, April 30, 2020

InflaRx up on bullish call at Raymond James

Citing “imminent data” from its COVID-19 trial and an autoimmune disorder study, Raymond James’ Steven Seedhouse has upgraded InflaRx (NASDAQ:IFRX) to Outperform with a $10 (85% upside) price target.
Preliminary data from the 30-patient study assessing IFX-1 in patients with severe COVID-19-induced pneumonia should be available this quarter.
Initial data on its ongoing study testing IFX-1 in a rare autoimmune disease called AAV should be available “soon” since enrollment was stopped at 19 due to pandemic disruptions.
https://seekingalpha.com/news/3566905-inflarx-up-11-premarket-on-bullish-call-raymond-james

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.